Less Ads, More Data, More Tools Register for FREE

Pin to quick picksB.p Marsh Regulatory News (BPM)

Share Price Information for B.p Marsh (BPM)

Share Price is delayed by 15 minutes
Get Live Data
690.00    -6.00 (-0.86%)
Bid:
690.00
Ask:
700.00
Spread: 10.00 (1.449%)
Market Cap: £244.91m
BPM Live PriceLast checked at - London Stock Exchange

Intraday B.p Marsh Share Chart

Update on Sodalis Capital Limited

11 Mar 2026 07:00

RNS Number : 1305W
B.P. Marsh & Partners PLC
11 March 2026
 

11 March 2026

 

B.P. Marsh & Partners Plc

("B.P. Marsh", the "Company" or the "Group")

 

Update on Sodalis Capital Limited

 

B.P. Marsh & Partners Plc (AIM: BPM), the specialist investor in early-stage financial services businesses, notes yesterday's announcement by portfolio company Sodalis Capital Limited ("Sodalis") regarding the launch of Brecon Specialty Limited.

 

Background to Sodalis

 

B.P. Marsh invested in Sodalis in November 2025, a newly formed insurance intermediary group focused on UK and international underwriting, wholesale broking and related services.

 

Sodalis was established to pursue a buy-and-build strategy within the international insurance intermediary sector, targeting specialist underwriting and wholesale broking platforms across the UK, Europe and Asia.

 

B.P. Marsh's investment was made alongside Alliant Insurance Services, Inc. ("Alliant"), which also holds an approximate 27% shareholding in Sodalis. Alliant is the fifth largest insurance intermediary group globally, generating over $5bn of insurance brokerage annually.

 

Sodalis was founded by Colin Thompson, an insurance executive with over 30 years' experience in building and managing insurance intermediary businesses globally. Colin invested alongside B.P. Marsh and Alliant and also holds a c.27% shareholding in Sodalis.

 

Launch of Brecon Specialty by Sodalis Capital ("Brecon")

 

On 10 March 2026 Sodalis announced the launch of Brecon, a new London-based wholesale insurance broker.

 

Brecon has been created to provide specialist broking and risk advisory services to international independent brokers, as well as direct clients, with a focus on Cyber and Technology Errors & Omissions (E&O) risks globally.

 

Brecon, which will commence trading immediately, is led by David Rees as CEO, formally a Managing Director at Howden and a senior figure in the cyber insurance market. David will lead a team of 14, who collectively have over 100 years of combined experience across cyber insurance and the London insurance market.

 

The team is made up of experienced practitioners with long-standing relationships across insurers and syndicates operating in the Lloyd's and London company markets, positioning Brecon to provide specialist expertise and access to capacity for complex cyber and technology liability risks.

 

The launch of Brecon is entirely consistent with Sodalis' strategy at inception: to build a diversified international specialty insurance platform.

 

David Rees, CEO of Brecon, commented:

 

"Brecon was established to offer a focused independent broker in the London market. Our broker partners and clients will benefit from best-in-class service and access to considerable capacity, delivered by a team of cyber specialists that are at the top of their game."

 

Colin Thompson, Founder and CEO of Sodalis, commented:

 

"We are delighted that David and his team have joined Sodalis to launch Brecon Specialty. Their deep expertise in cyber and technology E&O, together with their long-standing relationships across the London market, creates a strong platform from which to build a leading specialist broker serving clients and intermediary partners globally."

 

Dan Topping, CEO at B.P. Marsh, commented:

 

"We are pleased to see the launch of Brecon Specialty as part of Sodalis' broader growth strategy. The team brings deep expertise in cyber insurance and strong relationships across the London market. This development further demonstrates Sodalis' ambition to build a high-quality international specialty insurance platform."

 

For further information on B.P. Marsh, its strategy and current portfolio, please visit www.bpmarsh.co.uk or contact: 

 

B.P. Marsh & Partners Plc

Daniel Topping / Alice Foulk

 

+44 (0)20 7233 3112

Nominated Adviser & Joint Corporate Broker:

Singer Capital Markets Advisory LLP

Charles Leigh-Pemberton / Peter Steel / James Todd

 

+44 (0)20 7496 3000

Joint Corporate Broker:

Investec Bank plc

Christopher Baird / David Anderson / Maria Gomez de Olea

 

+44 (0)20 7597 5970

Financial PR & Investor Relations:

Tavistock

Simon Hudson / Katie Hopkins / Kuba Stawiski

 

bpmarsh@tavistock.co.uk

+44 (0)20 7920 3150

Forward-looking statements

 

This announcement may include statements, beliefs or opinions that are, or may be deemed to be, "forward-looking statements". These forward-looking statements may be identified by the use of forward-looking terminology, including the terms "believes", "estimates", "plans", "projects", "anticipates", "targets", "aims", "continues", "expects", "intends", "hopes", "may", "will", "would", "could" or "should" or, in each case, their negative or other variations or comparable terminology, or by discussions of strategy, plans, objectives, goals, future events or intentions. No representation or warranty is made that any of these statements or forecasts will come to pass or that any forecast results will be achieved. Forward-looking statements may and often do differ materially from actual results. Any forward-looking statements contained in the announcement speak only as of their respective dates, reflect B.P. Marsh's current view with respect to future events and are subject to risks relating to future events and other risks, uncertainties and assumptions relating to B.P. Marsh's business, results of operations, financial position, liquidity, prospects, growth and strategies.

 

Except as required by any applicable law or regulation, B.P. Marsh expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained in this announcement or any other forward-looking statements it may make whether as a result of new information, future developments or otherwise. 

- Ends -

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCSFAEESEMSEDD
Date   Source Headline
29th May 20267:00 amRNSDirector/PDMR Shareholding
27th May 20267:01 amRNSFinal Results for the Year to 31 January 2026
27th May 20267:00 amRNSDirectorate change
13th May 20267:00 amRNSTransaction in Own Shares
6th May 20267:00 amRNSNotice of Results and Investor Presentation
24th Apr 20265:50 pmRNSTransaction in Own Shares
20th Apr 20265:25 pmRNSSIP Awards, PDMR Dealings, Treasury Shares, TVR
16th Apr 20267:00 amRNSDeferred Consideration Receipt & Special Dividend
14th Apr 20267:00 amRNSTransaction in Own Shares
8th Apr 20267:00 amRNSTransaction in Own Shares
2nd Apr 20267:00 amRNSFollow-on equity purchase in Pantheon
31st Mar 20267:00 amRNSTransaction in Own Shares
30th Mar 20263:52 pmRNSDirector/PDMR Shareholding
26th Mar 20267:00 amRNSNew Share Buyback Programme
18th Mar 20267:00 amRNSNew Investment: Nine Edge Wealth Limited
18th Mar 20267:00 amRNSNew Investment: Ventura Risk Partners Holdings
17th Mar 20264:48 pmRNSSale of Interest in Amiga to Sodalis
11th Mar 20267:00 amRNSUpdate on Sodalis Capital Limited
24th Feb 20267:00 amRNSTrading Update
6th Feb 20267:00 amRNSPurchase of Own Shares and Total Voting Rights
5th Feb 202611:44 amRNSTransaction in Own Shares
21st Jan 20267:00 amRNSInterim Dividend Declaration
18th Dec 20257:00 amRNSTransaction in Own Shares & Total Voting Rights
15th Dec 20257:00 amRNSSpecial Dividend Declaration
11th Dec 20257:00 amRNSAppointment of Nominated Adviser and Joint Brokers
2nd Dec 20257:00 amRNSChange in Executive Directorship Roles
27th Nov 20256:17 pmRNSTransaction in Own Shares
27th Nov 20257:00 amRNSNew Investment: Sodalis Capital Limited
25th Nov 20254:55 pmRNSTransaction in Own Shares
24th Nov 20255:05 pmRNSTransaction in Own Shares
24th Nov 20257:00 amRNSTransaction in Own Shares
21st Nov 20257:00 amRNSTransaction in Own Shares
20th Nov 20257:00 amRNSTransaction in Own Shares
19th Nov 20257:57 amRNSTransaction in Own Shares
17th Nov 20257:00 amRNSTransaction in Own Shares
13th Nov 202512:38 pmRNS-RB.P. Marsh to present at MelloLondon
11th Nov 20255:08 pmRNSTransaction in Own Shares
7th Nov 20257:00 amRNSTransaction in Own Shares
6th Nov 20257:00 amRNSTransaction in Own Shares
5th Nov 20257:00 amRNSTransaction in Own Shares
4th Nov 20257:00 amRNSTransaction in Own Shares
30th Oct 20257:00 amRNSTransaction in Own Shares
28th Oct 20257:01 amRNSTransaction in Own Shares
28th Oct 20257:00 amRNSSale of Stewart Specialty Risk Underwriting
27th Oct 20257:00 amRNSTransaction in Own Shares
21st Oct 20257:00 amRNSHalf-year Results
7th Oct 202511:15 amRNSNotice of HY Results and Investor Presentation
30th Sep 20253:52 pmRNSNew Investment: Oneglobal Broking Holdings Limited
23rd Sep 20257:00 amRNSTrading Update
22nd Sep 20253:23 pmRNSNew Investment

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.